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Abstract
Background: Preconception allergen immunization prevents neonatal allergen sensitization in mice by a complex
interaction between regulatory cells/factors and antibodies. The present study assessed the influence of maternal
immunization with ovalbumin (OVA) on the immune response of 3 day-old and 3 week-old offspring immunized
or non-immunized with OVA and evaluated the effect of IgG treatment during fetal development or neonatal
period.
Results: Maternal immunization with OVA showed increased levels of FcgRIIb expression in splenic B cells of
neonates, which were maintained for up to 3 weeks and not affected by additional postnatal OVA immunization.
Maternal immunization also exerted a down-modulatory effect on both IL-4 and IFN-g-secreting T cells and IL-4 and
IL-12- secreting B cells. Furthermore, immunized neonates from immunized mothers showed a marked inhibition of
antigen-specifc IgE Ab production and lowered Th2/Th1 cytokine levels, whereas displaying enhanced FcgRIIb
expression on B cells. These offspring also showed reduced antigen-specific proliferative response and lowered B cell
responsiveness. Moreover, in vitro evaluation revealed an impairment of B cell activation upon engagement of B cell
antigen receptor by IgG from OVA-immunized mice. Finally, in vivo IgG transference during pregnancy or
breastfeeding revealed that maternal Ab transference was able to increase regulatory cytokines, such as IL-10, in the
prenatal stage; yet only the postnatal treatment prevented neonatal sensitization. None of the IgG treatments
induced immunological changes in the offspring, as it was observed for those from OVA-immunized mothers.
Conclusion: Maternal immunization upregulates the inhibitory FcgRIIb expression on offspring B cells, avoiding
skewed Th2 response and development of allergy. These findings contribute to the advancement of prophylactic
strategies to prevent allergic diseases in early life.
Background
Several studies with mouse or rat models have demon-
strated that maternal immunization can suppress speci-
fic IgE Ab response in the offspring [1-10]. Targeting
the maternal immune system is an attractive strategy for
controlling early neonatal allergen sensitization, when
infants with pronounced Th2 responses are susceptible
to allergic diseases [11,12].
It has been shown that preconception immunization
of female mice with the dust mite Dermatophagoides
pteronyssinus (Der p) transfers high titers of antibodies
through the transamniotic/transplacental route and
TGF-b-enriched milk by breast feeding [7], leading to
the inhibition of both allergen-specific IgE Ab and Th2
cytokine production [9]. The efficacy of maternal immu-
nization was confirmed by the ability to prevent neona-
tal allergen sensitization when mothers were intensively
exposed to Ag during the breastfeeding period [8].
Moreover, breastfeeding-induced tolerance, associated
with the presence of TGF-b during lactation, seems to
be mediated by regulatory CD4+ T lymphocytes and
dependent on the TGF-b signaling in T cells, but does
not require the transfer of immunoglobulin [13]. In fact,
several mechanisms acting synergistically, involving
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and factors that are major components in maternal
immunomodulation, are required to prevent offspring
allergic responses.
Circulating MatAb in the offspring may diminish
allergen processing and presentation by antigen-pre-
senting cells (APCs) to T cells, preventing neonatal
sensitization [11]. The immune complex of MatAb
involving inhaled or ingested allergens could be cleared
before priming the neonate immune system, avoiding
I g EA bp r o d u c t i o n .M a t A bt r a n s f e r r e dt ot h eo f f s p r i n g
may recognize the idiotype in the B cell antigen recep-
tors (BCRs) or T cell antigen receptors (TCRs) of
immature fetal B or T cells, respectively, interfering
with the idiotype repertoire selection [14,15] or,
through anti-idiotype interaction with BCRs, promot-
ing a long-lasting inhibitory effect [16,17]. Further-
more, immune complex of MatAb engage BCRs with
the IgG receptor on B cells (Fcg RIIB), delivering a
potent inhibitory signal that prevents B cells prolifera-
tion and Ab secretion [18]. Nonetheless, so far, there
has been no evidence in allergy related studies to sug-
gest that MatAb affect the activation of inhibitory sig-
nals through FcgRIIb in neonatal B cells.
In the present work, the impact of preconception
immunization with ovalbumin (OVA) on the B and
T cell function in neonates or lactating mice was
assessed. Also, B and T cell responses were evaluated
after IgG injections in pregnant mice or in neonates.
Results
Up-regulation of FcgRIIb on B cells of offspring from
mothers subjected to preconception immunization
with OVA
Mouse mothers in the prenatal stage were immunized
with OVA and the immunization effect on their offspring
was evaluated by measuring immune response-B cells in
particular-in 3 day-old neonates and, later, during the
weaning period (3 weeks old). The absolute number of
splenic B cells (B220+IgM+) of neonates (3 d-o) from
immunized mother (1.36 × 10
6 cells ± 0.12) was similar
to those from nonimmunized mothers (1.06 × 10
6 cells ±
0.11). After neonatal immunization, it was observed an
increase in the absolute number of splenic B cells in the
20 d-o offspring from immunized mothers (42.04 × 10
6
cells ± 3.58) as compared to their counterparts from non-
immunized mothers (31.13 × 10
6 cells ± 1.23).
Figure 1a shows that maternal immunization with
OVA induced slight changes in the activation molecule
expression in B cells in neonate mice, such as a dimin-
ished expression of CD40 compared to the control
group; in the 20 day-old group from immunized
mothers, only CD23 expression appeared to be altered
as compared to the control group (Figure 1b).
Neonatal B cells of 3 d-o offspring from immunized
mothers showed an increased expression of the inhibi-
tory receptor, FcgRIIb, which was then maintained for
3 weeks, whether the offspring was subjected to neona-
tal OVA immunization or not (Figure 2).
Maternal immunization correlated with high levels of
anti-OVA IgG1 and IgG2a Ab in the pups, and when this
offspring was submitted to neonatal immunization, both
IgG subclasses were inhibited (Figure 3a). The levels of
I g GA bd e t e c t e di nt h ei m m u n i z e do f f s p r i n gr e p r e s e n t
both the vertically transmitted from the mothers and the
offspring’s own production [9]. The decrease in the IgG1
and IgG2a Ab levels of immunized offspring from immune
mothers indicates that MatAb down-modulate offspring
Ab production. The absence of IgM in the offspring,
showing no sensitization, suggests that there had been no
allergen transfer from mothers. Induction of anti-OVA
IgM production was only observed after neonatal immuni-
zation. Preconception immunization with OVA signifi-
cantly diminished anti-OVA IgE Ab production in the
immunized offspring (Figure 3b). Furthermore, maternal
immunization decreased the percentage of splenic cyto-
kine-secreting B cells (IL-4 and IL-12) and CD4+ T cells
(IL-4 and IFN-g) in the nonimmunized offspring, as com-
pared to the control group (Figure 3c and 3d).
Figure 1 Influence of maternal immunization with OVA on the
ex vivo expression of B cell-costimulatory molecules from
nonimmunized offspring. BALB/c offspring from mothers
immunized with OVA prior to conception were evaluated at 3 d-o
(A) or 20 d-o (B) for CD80, CD86, CD40 and CD23 expression on
splenic B cells (B220+IgM+). The data obtained by flow cytometry
represent the mean ± SEM of 12 mice per group. *P ≤ 0.05
compared to offspring from nonimmunized mothers.
Victor et al. BMC Immunology 2010, 11:11
http://www.biomedcentral.com/1471-2172/11/11
Page 2 of 10Neonatal immunization with OVA led to a decreased
number of IL-4 and IL-12- secreting B cells and IL-4
and IFN-g- secreting CD4+ T cells in the offspring from
control mothers. Moreover, immunized offspring from
immune mothers showed an even lower percentage of
IL-12-secreting B cells and IL-4- secreting CD4+ T cells
(Figure 3). These findings reveal that early sensitization
to OVA is immunomodulatory in pups from both
immune and non-immune mothers compared to non-
immunizedcontrols and that this effect is more pro-
nounced in pups from immune mothers. Furthermore,
maternal immunization significantly lowered the off-
spring Ag-specific proliferative response (Figure 4a) and
B cell responsiveness to CpG stimulus as compared to
the control group (Figure 4b). Also, to evaluate whether
up-regulation of FcgRIIb expression on B cells could be
related to the functional inhibition of B cell activation
upon BCR engagement, the proliferative response of B
cells from non-immunized mice to anti-IgM crosslinking
in presence of IgG and OVA was assessed. The results
showed that B cell activation by BCR-crosslinking was
significantly inhibited in t h ep r e s e n c eo fI g Ga n dO V A
complex at the highest IgG concentration (Figure 4c). In
a d d i t i o n ,ar e d u c t i o ni nI L - 4s e c r e t i o nu p o nO V A
stimulation in offspring from immunized mothers was
observed (Figure 4d). The latter result suggests that the
maternal immunization prevented offspring allergen sen-
sitization by inhibiting the IgE anaphylactic Ab produc-
tion and down-modulating the Th2 cytokine production,
while simultaneously up-regulating FcgRIIb expression
on B cells.
Effect of IgG transference in the gestational or
neonatal periods
To reveal the impact mediated by MatAb, per se, on the
offspring’s B cell function, purified IgG from immunized
or nonimmunized mothers was i.v. injected into preg-
nant or neonate mice.
Figure 5 shows that passive IgG transference from
immunized mothers to neonates inhibited IgE Ab
response compared to the group receiving IgG from
nonimmunized mice. However, no changes were
observed in the expression of activation/inhibition mole-
cules on B cells or in the intracellular cytokines of B or
CD4+ T cells (Figure 5).
To elucidate the effect of MatAb during fetal develop-
ment, pregnant mice were subjected to i.v. IgG injec-
tions on days 10, 15 and 20 of gestation. After delivery,
Figure 2 Maternal immunization with OVA upregulates FcgRIIb expression on B cells from offspring. BALB/c offspring from mothers
immunized with OVA prior to conception or from control mothers (nonimmunized) were immunized (3 d-o) or not with OVA and evaluated at
3 d-o and 20 d-o for FcgRIIb expression on splenic B cells (B220+IgM+). The data obtained by flow cytometry represent the mean ± SEM of 12
mice per group. Histogram of B cell FcgRIIb expression depicting the cells from offspring from immunized (shaded histogram, Mean fluorescence
intensity (MFI) in bold numbers) and nonimmunized mothers (white histogram, MFI in light numbers). *P ≤ 0.05 compared to offspring from
nonimmunized mothers, #P ≤ 0.05 compared to nonimmunized offspring (20 d-o) from control mothers.
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period, after neonatal immunization.
Non-immunized offspring (3 d-o) from mothers that
received IgG from immune mice during pregnancy
showed lower expression of CD40 and CD23 molecules
on B cells compared to those from pregnant mothers
that received non-immune IgG. As for the FcgRIIb
expression, the increase observed in pups from
immune mothers was not statistically significant (Fig-
ure 6). After neonatal immunization, these offspring
(20 d-o) showed IgE Ab response and FcgRIIb expres-
sion on B cells at similar levels to those from mothers
treated with control IgG (Figure 7). Curiously, a high
percentage of ex vivo IL-10-producing CD4+ T cells
was detected in offspring from mothers treated with
immunized IgG during pregnancy, with no changes in
the IL-4 and IFN-g cell numbers or in cytokine-secret-
ing B cells.
The results showed that MatAb passively transferred
to neonates may prevent IgE Ab response; however,
both IgG treatments failed to induce the immunological
responses observed in the offspring from OVA-immu-
nized mothers.
Discussion
Allergy prevention through maternal immunization with
specific allergens has been shown to be a promising pro-
phylatic way to avoid sensitization in early life and the
development of allergic diseases. The mechanisms
underlying the IgE Ab response, as a consequence of
maternal immunization, involve a complex interaction
of inhibitory MatAb, regulatory cytokines-including
TGF-b [8]-and regulatory T cells [13] that are yet to be
fully understood. MatAb have a crucial role in forming
immune complexes that are able to neutralize allergens
and prevent neonatal sensitization. Nonetheless the
effect of MatAb through BCR engagement on the B cell
function remains unclear.
Our results showed that maternal immunization up-
regulates the inhibitory IgG receptor, FcgRIIb, on B cells
of neonates at very early age (3 d-o) and in young mice.
Furthermore, high levels of Ag-specific IgG Ab were
transferred to the pups by transplacental and breastfeed-
ing routes, allowing the crosslinking of Fcg RIIB through
the IgG-Ag complex and leading to the B cell inhibition.
The inhibitory coreceptors contain immunoreceptor tyr-
osine-based inhibition motifs (ITIMs) in the cytoplasmic
Figure 3 Effect of maternal immunization with OVA on the immune response of nonimmunized or immunized neonates. Neonate pups
(3 d-o) from control or immune mothers were immunized or not with OVA and evaluated (20 d-o) for: (A) IgG1, IgG2a and IgM by ELISA;
(B) anti-OVA IgE Ab levels by PCA reaction; (C) intracellular cytokines of splenic B cells (B220+) or (d) CD4+ T cells after 24 h incubation with
10 μg/mL brefeldin A by flow cytometry. The results represent the mean ± SEM of 12 mice per group. *P ≤ 0.05 compared to offspring from
nonimmunized mothers, #P ≤ 0.05 compared to nonimmunized offspring from control mothers, ￿ P ≤ 0.05 compared to control offspring from
immune mothers.
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vitro activation of B cells [19,20] and immature B cells,
which are highly sensitive to FcgRIIB inhibitory signaling
[21]. Also, it has been shown that all B cell stages
express FcgRIIB and that crosslinking induces apoptosis
of plasma cells, which may help to control their home-
ostasis [22]. In this work, the functional inhibition of B
cell activation upon anti-IgM stimulation in presence of
IgG-OVA complex suggests that this interaction up-reg-
ulate FcgRIIB expression, leading to the B cell prolifera-
tive inhibition. In addition, it has been shown that the
inhibitory Fc receptor is also required to maintain toler-
ance [23]. In lupus-prone mouse strains, partial restora-
tion of FcgRIIB on B cells is sufficient to restore
tolerance and prevent autoimmunity [24,25]. Therefore,
increasing FcgRIIB levels on B cells may be an effective
way to treat autoimmune diseases.
Our data showed that maternal immunization modu-
lates the expression of B cell markers, such as CD23,
CD40 and CD44, and reduces the number of IL-12 and
IL-4-secreting B cells in nonimmunized offspring. As B
cells account for the majority of spleen’sc e l l s ,t h e ym a y
represent an important cytokine source for CD4+
T cells. Also, considering the role of IL-12 in Th1 acti-
vation [26], the diminished number of IL-12-secreting
B cells in the offspring from immunized mothers may
partially contribute to the reduction in IFN-g-secreting
CD4+ T cells. The control of Th2 function, as verified
by the reduced percentage of IL-4-secreting CD4+
T cells and IL-4 secretion, was also down-modulated in
offspring from immunized mothers. Therefore, the con-
trol of Th1/Th2 cytokine secretion in offspring by
maternal immunization seems to be an important strat-
egy to prevent allergen sensitization.
The prophylactic role of maternal immunization was
reinforced by neonatal offspring immunization with
OVA, as both procedures suppressed the anaphylactic
IgE antibodies and allergen-specific proliferative
response. The down-modulation of IL-4 production may
help to maintain enhanced FcgRIIb expression on B
cells in immunized offspring, corroborating to a report
showing that IL-4 reduced FcgRIIb-mediated B cell sup-
pression [27]. Indeed, the B cell anergic status in immu-
nized offspring from immunized mothers, hereby
observed, was characterized by diminished proliferative
responsiveness to CpG oligodeoxynucleotides and sup-
pression of B-cell cytokine secretion. The presence of a
TLR-9 agonist response revealed the commitment of
other signaling pathways besides BCR’s in offspring
from immunized mothers. Further investigation is
required to ascertain whether signaling via ITIM
through FcgRIIB acts as anti-inflammatory by inhibiting
NFB signaling via TLR9 activation. It has been shown
that the nonpathogenic immune complex/Ig negatively
regulates TLR4-triggered in f l a m m a t o r yr e s p o n s ei n
macrophages, down-regulating NF-B activation
through FcgRIIB-dependent PGE2 [28].
The complex immunological interactions that occur to
maintain maternal-fetal tolerance involve many specia-
lized mechanisms to protect the fetus, which expresses
paternal Ags, from maternal immune attack [29-32].
Figure 4 Impaired B cell activation by BCR-crosslinking of
offpring from immunized mothers. Neonate pups (3 d-o) were
immunized with OVA and evaluated (20 d-o) for: (A) proliferative
spleen cell response to OVA; (B) purified B-cell response for CpG
oligodeoxynucleotide type B (5 μg/mL) stimuli; (C) purified B cell
from nonimmunized mice incubated with F(ab’)2 anti-mouse IgM
Ab (50 μg/mL) in the presence of IgG from from OVA-immunized
unrelated adult mice (10, 50, 100 μg/mL), or monoclonal antibody
anti-OVA (a OVA, 5 μg/mL) plus OVA (10 μg/mL), incubated for 96
h [data expressed in Stimulation Index (S.I.)]; (D) cytokine
measurements in the supernatants of spleen cell culture after 72 h
of stimulation with OVA by cytometric bead array. The results
represent the mean ± SEM of 9 mice per group. *P ≤ 0.05
compared to offspring from nonimmunized mothers.
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allogeneic responses against the fetus, regulatory
mechanisms-like the maternal CD4+CD25+ regulatory
T cell pool-are systemically expanded in syngeneic preg-
nant mice [29]. The mechanisms involved in maternal-
fetal tolerance, even in a syngeneic system, may some-
how contribute to control the exacerbation of a Th2
response to the allergen. Previously, our group observed
that maternal immunization with Der p was able to con-
trol the exacerbation of Th2 responses to this allergen
in the offspring [9]. In fact, adoptively transferring aller-
gen-specific Th cells to females before mating may
cause the offspring to develop asthma [33].
Moreover, maternal adaptive immunity to selective
antigens may influences postnatal B cell and antibody
responses in offspring [34]. Maternal oxidized LDL
immunization before pregnancy induces in offspring an
increased IgM Ab to selective OxLDL epitopes, reducing
atherosclerosis in offspring. This maternal approach
assessed in mice and rabbits point to new strategies to
protect offspring against a range of pathogens the
mother has become immune, either spontaneously or as
result of immunization.
Passive IgG transference was performed to assess the
regulatory effect of IgG on the development of fetuses
or neonates. We observed that only postnatal IgG injec-
tion was able to inhibit offspring IgE Ab response, not
interfering with FcgRIIb expression on B cells. Consider-
ing that prenatal IgG transference occurs through FcRn,
a neonatal IgG Fc receptor [35], independently of Ab
specificity, the amount of anti-OVA Ab may not have
been enough to neutralize the allergen during offspring
immunization, as occurred in offspring treated with IgG
at the postnatal stage. Curiously, IgG treatment during
pregnancy induced an increased percentage of IL-10-
secreting CD4+ T cells after immunization. Moreover,
IL-10 is an important regulatory cytokine that can help
limit Th1 cytokine production [36] and may represent a
regulatory mechanism triggered by the antibodies, lead-
ing to idiotypic interactions between TCR and maternal
antibodies. In fact, it has been demonstrated that idioty-
pic interactions between maternal Ab with BCR or TCR
Figure 5 Effect of passive IgG transference to neonates on B and T cell responses. Neonate pups (3 d-o) from nonimmunized mothers
injected with IgG from nonimmunized or immunized mothers and simultaneously immunized with OVA were evaluated (20 d-o) for: (A) anti-
OVA IgE Ab levels by PCA reaction; (B) B cell FcgRIIb expression (B220+IgM+) and histogram of FcgRIIb expression on B cells of offspring from
immunized (shaded histogram, MFI in bold numbers) or nonimmunized mothers (white histogram, MFI in light numbers); (C) intracellular
cytokines of splenic B cells (B220+) or (D) CD4+ T cells after 24 h incubation with 10 μg/mL brefeldin A; data shown in B-D were obtained flow
cytometry. The results represent the mean ± SEM of 9 mice per group. *P ≤ 0.05 compared to offspring from nonimmunized mothers.
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phocyte repertoire [14,15].
Conclusions
Our findings showed that the mechanisms involved in
the regulation of allergic response by maternal immuni-
zation with the allergen ovalbumin are mediated by a
complex interaction of regulatory cells/cytokines and
antibodies. The MatAb complex alters the progeny
immune repertoire through mechanisms that are yet to
be fully understood. Nonetheless, there are sufficient
and compelling data to justify the research and develop-
ment of new protocols based on maternal vaccination to
prevent allergic diseases.
Methods
Animals
BALB/c mice of both sexes (8-10 weeks-old) were
obtained from the animal facilities of the São Paulo
University Medicine School. Wistar Furth rats of both
sexes, 3-4 months-old and bred in our own laboratory’s
animal facilities, were used for passive cutaneous ana-
phylaxis (PCA) reaction studies. All the experiments
were approved by the Ethics Committee for Animal
Research of the Institute of Biomedical Sciences.
Experimental Protocols
Preconception immunization
Female BALB/c mice were immunized s.c. with 150 μg
ovalbumin (OVA, grade V, Sigma-Aldrich, St Louis,
MO) in 6 mg Al(OH)3 and i.p. boosted with 100 μg
OVA without adjuvant, on days 10 and 20 after immu-
nization, as described previously [8]. One day later, the
females were mated with nonimmunized male BALB/c
mice.
Offspring immunization
Three day-old mice of both sexes were i.p. immunized
with 10 μg OVA in 0.6 mgAl(OH)3, as described
Figure 6 Effect of passive IgG transference to pregnant mice on neonatal B cell FcgRIIb expression. Nonimmunized pregnant mice were
injected with IgG from nonimmunized or immunized mothers. Nonimmunized neonates were evaluated (3 d-o) for: (A) CD80, CD86, CD40, and
CD23 molecule expression on splenic B cells (B220+) and (B) B cell FcgRIIb expression (B220+IgM+) by flow cytometry. Histogram of FcgRIIb
expression on B cells of offspring from immunized (shaded histogram, MFI in bold numbers) or nonimmunized mothers (white histogram, MFI in
light numbers). The results represent the mean ± SEM of 6 mice per group. *P ≤ 0.05 compared to offspring from nonimmunized mothers.
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Page 7 of 10Figure 7 Effect of passive IgG transference to pregnant mice on offspring’s B and T cell responses. Nonimmunized pregnant mice were
injected with IgG from nonimmunized or immunized mothers. Offspring immunized with OVA were evaluated (20 d-o) for: (a) anti-OVA IgE Ab
levels by PCA reaction; (b) CD80, CD86, CD40 CD23 molecule expression on splenic B cells (B220+); (c) B cell FcgRIIb expression (B220+IgM+) by
flow cytometry. Histogram of FcgRIIb expression on B cells of offspring from immunized (shaded histogram, MFI in bold numbers) or
nonimmunized mothers (white histogram, MFI in light numbers); (d) intracellular cytokines of splenic B cells (B220+) and (e) CD4+ T cells after
424 h incubation with 10 μg/mL brefeldin A, all by flow cytometry. The results represent the mean ± SEM of 6 mice per group. *P ≤ 0.05
compared to offspring from nonimmunized mothers.
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p. injection of 10 μg of OVA in saline solution and were
bled after 7 days.
Passive prenatal or postnatal IgG transference
IgG antibodies from sera of mice immunized with OVA
(40 days after immunization) or nonimmunized mice
were purified using Melon Gel IgG Spin Purification kit,
according to the manufacturer’si n s t r u c t i o n s( P i e r c e ,
Rockford, IL), and stored at -70°C until use. IgG mea-
surements were performed by ELISA. Prenatal IgG trans-
ference was performed in pregnant females by i.v. route
with 200 μg of IgG on days 10, 15 and 20 of gestation.
Postnatal IgG transference was performed on offspring at
2, 5, 10 and 15 days-old by i.p. route with 10, 30, 60 and
60 μg of IgG, respectively. The non-immunized offspring
were assessed at 3 days-old or, when submitted to neona-
tal immunization with OVA (3 d-o), at 20 d-o.
Passive cutaneous anaphylaxis (PCA)
IgE antibodies were estimated by PCA in rats according
to Mota and Wong [37]. Serum dilutions were inoculated
intradermally (100 μL) on the shaved backs of rats. After
18 h, the rats received an injection of 0.5 mg OVA in 1.0
mL of 0.5% Evans Blue solution through a tail vein. PCA
titers were expressed as the reciprocal of the highest dilu-
tion that caused a spot larger than 5 mm in diameter.
Determination of Ab levels
OVA-specific IgG1, IgG2a and IgM antibodies were
measured by ELISA, as previously described [8]. The
results were expressed as antibodies titers with refer-
ence to serial dilution of a titrated serum pool from
immunized adult mice with high levels of specific
Abs.
Proliferation assay with tritiated thymidine
Spleen aseptically collected from 20 day-old mice was
pressed through a cell strainer (BD Biosciences, Bedford,
MA) in RPMI-1640 supplemented with 10% FCS (Hyclone
III, Lotan, CT). The red blood cells were lysed using ACK
Lysing Buffer (Biosource, Rockville, MD) for 90 sec. Rest-
ing B cells were purified from splenic mononuclear cells
(SMC) using magnetic microbeads from a B cell isolation
kit (Miltenyi Biotec, CA, EUA), and enrichment was more
than 95% when verified by flow cytometry.
Cultures of SMC (2.0 × 10
5 cells/0.2 mL) in 96-well
microplates (Costar, Cambridge, MA, UK) were stimu-
lated with OVA (200 μg/mL; Sigma) at 37°C in a humi-
dified 5% CO2 incubator. B cell cultures (5 × 10
5 cells/
0.2 mL) were incubated with 5 μg/mL of CpG olideoxy-
nucleotide (ODN) type B (1826 - 5’ TCC ATG ACG
TTC CTG ACG TT 3’ synthetized by Eurogentec, Bel-
gium). Other B cell cultures (8 × 10
5 cells/0.2 mL) were
incubated with 50 μg/mL of F(ab’)2 goat anti-mouse
IgM (Southern Biotechnology Ass., Birmingham, AL)
and concentrations of purified IgG (10-100 μg/mL) from
immunized mice with OVA or 5 μg/mL of mouse
monoclonal to ovalbumin (Abcam Inc, Cambridge, MA)
and 10 μg/mL of OVA (Sigma). Thymidine incorpora-
tion was measured on day 4 of culture after 18 h of
being pulsed with 1 μCi [
3H]thymidine (Amersham
Biosciences AB, Uppsala, Sweden).
In vitro cytokine production
Splenic mononuclear cells were cultured in 48-well
plates (Costar) in RPMI-1640 supplemented with 10%
FCS with OVA (200 μg/mL, Sigma) for 72 h; the cell-
free supernatants were stored at -70°C. Cytokines were
measured using a Th1/Th2 cytokine bead array kit (Bec-
ton Dickinson, San Diego, CA, USA), by flow cytometry
(FACSCAlibur, BD, San Jose, CA).
Flow cytometry
To evaluate surface markers on SMCs the following mAbs
were used: PerCy P-conjugated anti B220, anti-CD4,
FITC- labeled anti-IgM (Southern Biotech. Ass., Birming-
ham, AL), R-PE-conjugated anti-CD40, anti-CD80, anti-
CD86, anti-CD23 and anti-CD16/32 (FcgRIII/II) from BD-
Pharmingen. All flow cytometry staining procedures were
performed at 4°C in PBS/1% BSA (Sigma). Cells were then
washed in PBS/1% BSA and flow cytometry buffer before
analysis of 10,000 gated events by Coulter Epics XL-MCL
(Beckman-Coulter, Miami, FL, U.S.A.). To determine
intracellular cytokines, SMCs were cultivated in 24-well
plates (Costar) with Brefeldin A (10 μg/mL, Sigma) for
24 h. Next, cells were washed with PBS-BSA solution,
labeled with fluorochrome-conjugated CD4 or B220. After
fixation and 0.5% saponin (Sigma) permeabilization proce-
dure samples were incubated with fluorochrome-conju-
gated anti-IL-4, IFN-g, IL-10 and IL-12p40/p70 antibodies,
or the respective isotype controls (BD-Pharmingen) were
used in all analysis, fixed and stored at 4°C for flow cyto-
metry acquisition.
Statistical analysis
Values for all measurements are expressed as mean ±
SEM. Differences between groups were considered sig-
nificant when P values were < 0.05, using the Mann-
Whitney test.
Abbreviations
MatAb: maternal antibodies; d-o: day old; OVA: ovalbumin; FcgRIIB: IgG Fc
receptor; PCA: passive cutaneous anaphylaxis.
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